NEW YORK, July 31 (UPI) -- Maryland-based Medimmune pharmaceuticals expects to produce nearly five times the amount of H1N1 vaccine originally anticipated, its executives said.
GAITHERSBURG, Md., July 3 (UPI) -- U.S. firm MedImmune said Tuesday it has begun dosing studies of its potential vaccine to prevent two common children's respiratory infections.
WASHINGTON, May 30 (UPI) -- Contamination concerns led the U.S. Food and Drug Administration to delay expanding approval of the nasal flu vaccine FluMist to very young children.
GAITHERSBURG, Md., March 29 (UPI) -- U.S. vaccine maker MedImmune said Thursday it has licensed reverse genetics technology to Sanofi pasteur to use in its flu vaccines.
GAITHERSBURG, Md., Nov. 9 (UPI) -- MedImmune said Thursday it filed an investigational new drug application with the U.S. Food and Drug Administration on a cell-based flu vaccine.
GAITHERSBURG, Md., Aug. 14 (UPI) -- MedImmune said Monday it has responded to the questions the Food and Drug Administration raised about its CAIV-T flu vaccine.
GAITHERSBURG, Md., July 6 (UPI) -- MedImmune said Thursday the Food and Drug Administration approved its reverse genetics technology for producing flu vaccines.
GAITHERSBURG, Md., May 4 (UPI) -- The federal government has awarded a $170 million contract to MedImmune Inc. of Maryland for a flu vaccine. The five-year contract from the Health and Human Services Department is to develop cell-based seasonal and pandemic vaccines using its proprietary
WASHINGTON, Dec. 12 (UPI) -- MedImmune said Monday preliminary phase 3 results indicated its experimental intranasal flu vaccine, CAIV-T, may protect better than the injectable vaccine.
WASHINGTON, Dec. 9 (UPI) -- When health officials said last week flu vaccine supplies had been exhausted, they overlooked one manufacturer that still has millions of doses available.
